Related Experiment Videos
Neurohumoral mechanisms involved in congestive heart failure
Insights
Congestive heart failure (CHF) triggers compensatory mechanisms like increased vascular tone and fluid retention. Understanding these changes and peripheral circulation control offers new therapeutic targets for CHF.
Area of Science:
- Cardiology
- Pharmacology
- Physiology
Background:
- Congestive heart failure (CHF) induces compensatory biologic changes to counteract reduced blood flow.
- Key systems activated include the sympathetic nervous system, renin-angiotensin system, and arginine vasopressin release.
- These mechanisms result in heightened vascular tone and increased sodium/water retention.
Purpose of the Study:
- To explore the biologic changes in congestive heart failure (CHF).
- To understand the role of Angiotensin II in CHF pathophysiology.
- To review potential pharmacologic interventions targeting vascular tone and sympathetic activity.
Main Methods:
- Review of existing literature on CHF pathophysiology and pharmacology.
- Analysis of the roles of key neurohormonal systems (sympathetic nervous system, renin-angiotensin system).
- Discussion of pharmacologic agents targeting vascular tone and sympathetic modulation.
Main Results:
- Angiotensin II plays a critical role through vasoconstriction, norepinephrine release, and aldosterone stimulation.
- Converting enzyme inhibitors are established treatments for CHF.
- Emerging therapies include agents targeting presynaptic receptors and dopaminergic receptors for selective vasodilation.
Conclusions:
- Understanding the fine control of peripheral circulation in CHF is crucial.
- Appreciation of these mechanisms allows for more selective and innovative pharmacologic therapies.
- Targeting specific pathways offers potential for improved CHF management.
Abstract:
Congestive heart failure (CHF) promotes an array of biologic changes that are largely designed to compensate for reduced flow. These include activation of the sympathetic nervous system and the renin-angiotensin system, as well as the release of arginine vasopressin. The ultimate expression of these compensatory mechanisms is heightened vascular tone, increased sodium and water retention and antidiuresis. The peripheral circulation is normally under the fine control of circulating and neuronally released moieties, which can directly or indirectly alter vascular tone. Angiotensin II appears to be a key element in this regard because of its multiple biologic activities. Direct arteriolar vasoconstriction, facilitation of norepinephrine release and stimulation of aldosterone are some of the activities that are likely to be of major importance in the syndrome of CHF. Therefore, it is not surprising that converting enzyme inhibitors have a growing role as treatment. Other pharmacologic agents that can reduce sympathetic tone by acting on presynaptic receptors are being developed. Selective dilation of certain vascular beds may be possible with agents designed to interact with vascular dopaminergic receptors. The mechanisms whereby circulating epinephrine and norepinephrine modulate norepinephrine release and vascular tone are beginning to be understood and likely involve presynaptic, postsynaptic and nonsynaptic vascular receptors. A better appreciation of the mechanisms involved in the fine control of the peripheral circulation should allow for more selective and more imaginative pharmacologic therapy for CHF.